Sales of Acorda's Ampyra Off To Strong Start
This article was originally published in The Pink Sheet Daily
Because of a host of variables, estimating a peak sales figure based on actual demand has been tricky for analysts, but payers are covering the drug and patients are demanding it.
You may also be interested in...
Amid Uncertainties, Acorda Preps For Next Phase Of ACA: An Interview With Managed Markets Head Kent Rogers
With nine months to go before key aspects of the Affordable Care Act are implemented, Acorda Therapeutics’ head of managed markets, Kent Rogers, says he, like everyone, is ‘learning.” Acorda expects to have a game plan ready by mid-summer on how it will adapt its commercial strategy to ACA-initiated changes. Rogers also points out that the company may be less affected than others in the near term because Medicare already covers the majority of patients who take its multiple sclerosis drug Ampyra.
FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.
Acorda's challenge in marketing its multiple sclerosis drug Ampyra is not that it is a new drug, but that it is a new drug indicated to treat an aspect of the disease that has never before been treated